Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: CuttingEdge Bio	1/25/2021 9:58:36 AM
	Read Replies (1) of 3557

Can someone explain why they cannot develop Eylea-Ang2 Combo? I guarantee it would have the same result as this farici just did. It's the same damn concept. Why did Roche skirt by on "non-inferiority" with longer durability, and no improvement in vision, but yet REGN can't develop its combo toward the same goal. This is archaic regulatory BS that needs to be removed.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next